BDRX

Biodexa Pharmaceuticals Plc (BDRX) SWOT Analysis Analysis (2026)

Invetso Score: 3.8/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 4.8 (Moderate)

Negative cash conversion cycle indicates working-capital efficiency versus peers, because customer funding of operations can partially offset weak profitability.

Current and quick ratios above 2.0 provide liquidity resilience versus more levered peers, reducing near-term refinancing pressure despite operating losses.

Very low debt-to-equity suggests limited balance-sheet leverage versus capital-intensive peers, which preserves financial flexibility while the business remains unprofitable.

Weaknesses

Score:

TTM ROIC is deeply negative, showing capital is not earning its cost and leaving BDRX structurally behind profitable peers on value creation.

Net debt to EBITDA near 1.0 is manageable, but it still matters more for a loss-making peer because earnings coverage is weak and fragile.

Missing margin disclosure alongside negative returns signals limited demonstrated operating scale versus peers, making durable profitability harder to evidence.

Opportunities

Score:

If management converts the negative cash conversion cycle into sustained cash generation, BDRX could improve peer positioning without requiring large balance-sheet expansion.

High liquidity relative to peers creates room to fund development or commercialization initiatives, which can support future demand capture if execution improves.

Low leverage leaves capacity to absorb restructuring or investment cycles better than indebted peers, potentially widening strategic optionality over 2–5 years.

Threats

Score:

Persistent negative ROIC versus peers raises the risk of continued value destruction, especially if capital deployment fails to translate into durable operating gains.

Loss-making peers with stronger margins can outcompete BDRX on pricing and reinvestment, limiting its ability to defend share over time.

If working-capital efficiency reverses, the current liquidity cushion could erode quickly because the business lacks strong earnings support.

Overall Score

Score:

BDRX’s peer positioning is weak overall because liquidity and working-capital efficiency are offset by deeply negative returns on capital and limited evidence of durable operating strength.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Biodexa Pharmaceuticals Plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →